Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Salvage Immunotherapy Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE Study)

NCT05103501 is registered in ClinicalTrials.gov with Shanghai Chest Hospital as lead sponsor.

NCT NCT05103501
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05103501 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Salvage Immunotherapy Combined With Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy (SINCERE Study)
Lead sponsor
Shanghai Chest Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
September 30, 2024
Enrollment
54 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal squamous cell carcinomas